Yahoo! Finance Search - Finance Home - Yahoo! - Help

Thursday, November 26 2015 7:30am ET - U.S. Markets open in 2 hours.
Industry Center - Biotechnology
Industry Center > Biotechnology > News
More On This Industry
· Summary
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Biotechnology News
Latest News
Wednesday, Nov 25, 2015
·Don't Forget Hot Sectors When Looking For New Stocks
at Investor's Business Daily, Inc. - Wed 5:33 pm ET
·Spark Therapeutics Announces Filing of Registration Statement for Proposed Public Offering
GlobeNewswire - Wed 5:21 pm ET
·Biotechs Weaken, But These Names Have Bullish Charts
at Investor's Business Daily, Inc. - Wed 5:19 pm ET
·Amgen applies to FDA for competitor drug to AbbVie's Humira
at MarketWatch - Wed 4:27 pm ET
·Amgen files for U.S. approval of biosimilar to Humira
Reuters - Wed 4:11 pm ET
·PharmAthene Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards
PR Newswire - Wed 4:11 pm ET
·Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration
PR Newswire - Wed 4:00 pm ET
·Why this company's $700 million bet could come up short
at - Wed 2:52 pm ET
·FDA Panel Seen As Bad For BioMarin, Good For Sarepta
at Investor's Business Daily, Inc. - Wed 2:34 pm ET
·KaloBios Attempts To Consolidate After Four Volatile Sessions
- Wed 2:10 pm ET
·Insys Led IBB’s Mid-Cap Stocks
- Wed 2:00 pm ET
·Cell Source to Present at the LD Micro Main Event
- Wed 2:00 pm ET
·Synthetic Biologics Reports that Data from the Phase 2 Trimesta™ Clinical Trial for Relapsing-Remitting Multiple Sclerosis were Published by Lead Principal Investigator
PR Newswire - Wed 1:20 pm ET
·Aeterna Zentaris Affirms Fundamental Strength of Business
CNW Group - Wed 1:00 pm ET
·Aeterna Zentaris Affirms Fundamental Strength of Business
PR Newswire - Wed 1:00 pm ET
·Housing stocks help push FTSE 100 to highest finish in 3 weeks
at MarketWatch - Wed 12:54 pm ET
·Brower Piven, a Maryland-Based Securities Litigation Law Firm, Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Osiris Therapeutics Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action
Business Wire - Wed 12:53 pm ET
·Here’s what former Sarepta CEO Chris Garabedian had to say about BioMarin’s drug panel
at - Wed 11:55 am ET
·Looking for Action? Choose Between Sadness or Madness
at - Wed 11:32 am ET
·Martin Shkreli: Who's Tim Sykes?
- Wed 11:19 am ET
More Latest News...

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Biotechnology Headlines
More Finance RSS Feeds

Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2015 Morningstar, Inc. All Rights Reserved. Company information © 2015 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2015, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?